Lubeluzole in acute ischemic stroke treatment: A double-blind study with an 8-hour inclusion window comparing a 10-mg daily dose of lubeluzole with placebo

Stroke

Volumn 31, Issue 11, 2000, Pages 2543-2551

  Diener, H C ^a   Cortens, M ^b   Ford, G ^g   Grotta, J ^d   Hacke, W ^e   Kaste, M ^f   Koudstaal, P J ^c   Wessel, T ^b  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b JANSSEN RESEARCH FOUNDATION   (Belgium)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f UNIVERSITY OF HELSINKI   (Finland)

^g NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Clinical trials; Lubeluzole; Neuroprotection; Stroke

Indexed keywords

LUBELUZOLE; PLACEBO;

AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEVER; HEADACHE; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; NEUROPROTECTION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0033766740     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.31.11.2543     Document Type: Article

References (28)

1. Lubeluzole protects sensorimotor function and reduces infarct size in a photochemical stroke model
2. Treatment of experimental foci ischemia in rats with lubeluzole
3. Lubeluzole blocks increases in extracellular glutamate and taurine in the peri-infarct zone in rats
4. Pharmacological reduction of electrophysiological diaschisis after photothrombotic ischemia in rat neocortex
5. Lubeluzole, a novel long-term neuroprotectant, inhibits the glutamate-activated nitric oxide synthetase pathway
6. Neuroprotection of lubeluzole is mediated through the signal transduction pathways of nitric oxide
7. Lubeluzole in acute ischemic stroke
8. Lubeluzole treatment of acute ischemic stroke
9. Multinational randomised controlled trial of lubeluzole in acute ischaemic stroke
10. Neuroprotection as initial therapy in acute stroke
11. Guidelines for the management of patients with acute ischemic stroke: A statement for healthcare professionals
12. Neuroprotectants in late clinical development: A status report
13. The European Stroke Scale
14. Functional evaluation: The Barthel Index
15. Early treatment of stroke with monosialoganglioside GM-1: Efficacy and safety results of the early stroke trial
16. Intravenous Nimodipine West European Stroke Trial (INWEST) of nimodipine in the treatment of acute ischaemic stroke
17. The Clomethiazole Acute Stroke Study (CLASS): Results of a randomised controlled study of clomethiazole versus placebo in 1360 acute stroke patients
18. A randomized trial of tirilazad mesylate in patients with acute stroke (RANTTAS)
19. Low molecular weight heparinoid, ORG 10172 (Danaparoid), and outcome after acute ischemic stroke
20. Selfotel in acute ischemic stroke: Possible neurotoxic effects of an NMDA antagonist
21. Hypervolemic hemodilution in acute ischaemic stroke: The Multicenter Austrian Hemodilution Stroke Trial (MAHST) Stroke
22. The Enlimomab Acute Stroke Trial: Final results
23. Lubeluzole plasma concentrations and outcome in acute ischaemic stroke
24. Considerations in the design of clinical trials of neuroprotective therapy in acute stroke
25. The International Stroke Trial (IST): A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19.435 patients with acute ischaemic stroke
26. CAST: Randomized placebo-controlled trial of early aspirin use in 20.000 patients with acute ischaemic stroke
27. Which targets are relevant for therapy of acute ischemic stroke?
28. Combination therapy stroke trial: rt-PA±lubeluzole